Ollin Biosciences is a biotechnology company focused on developing best-in-class therapies for serious eye diseases, applying computational protein engineering and AI-driven optimization to design and refine bispecific antibodies. The company emerged from stealth in September 2025 with an ambitious mission to challenge top-selling ophthalmology drugs through superior molecular design.
Ollin's strategy centers on bispecific antibodies, engineered proteins that can simultaneously engage two biological targets, an approach that can deliver greater efficacy and more durable responses than conventional single-target therapies. Designing such molecules to achieve the right potency, stability, and dosing profile is a difficult engineering problem, and Ollin leverages computational and AI-assisted protein engineering to optimize candidates across these properties before and during experimental development.
The company's lead clinical-stage program, OLN324, is a higher-potency, higher-molar-dose VEGF/Ang2 bispecific antibody in Phase 1b clinical development for retinal diseases such as wet age-related macular degeneration and diabetic macular edema, with enrollment of more than 150 patients completed in its lead study. Its second program, OLN102, is a first-in-class TSHR/IGF-1R bispecific antibody targeting thyroid eye disease and the underlying autoimmune condition of Graves' disease, with the potential for best-in-disease safety and efficacy.
Ollin launched with an initial $100 million in financing co-led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital, with additional backing from investors including Polaris Partners. The capital supports advancement of its clinical pipeline and continued engineering of next-generation ophthalmic bispecifics. By pairing computational protein design with a focused ophthalmology pipeline, Ollin aims to bring differentiated, potentially best-in-class therapies to patients with sight-threatening conditions.